Anti-Denosumab ELISA Assay Kit


The Anti-Denosumab ELISA Assay Kit is intended as an analytical tool for quantitative determination of Anti-Denosumab in serum, plasma, and cell culture supernatant.

SKU: KBI2026 Category:

Anti-Denosumab ELISA Assay Kit

The Anti-Denosumab ELISA Assay Kit is For Research Use Only

Size: 12×8 wells
Sensitivity: <10 ng/ml
Standard Range: 10-640 ng/ml
Incubation Time: 2.25 hours
Sample Type: Serum, Plasma, Cell Culture Supernatants
Sample Size: 100 µl
Alternative Name: Prolia, Xgeva

Assay Background

Denosumab (trade names Prolia and Xgeva) is a human monoclonal antibody for the treatment of osteoporosis, treatment-induced bone loss, metastases to bone and giant cell tumor of bone.Denosumab is contraindicated in people with low blood calcium levels.The most common side effects are joint and muscle pain in the arms or legs.Denosumab is a RANKL inhibitor which works by preventing the development of osteoclasts which are cells that break down bone (bone resorption). Anti-Drug Antibodies (ADA) may induce unwanted side effects in biopharmaceuticals. Hence, ADA has been subjected to increase in scrutiny by the regulatory authorities using immunogenicity safety studies. ADA has been observed in pre-clinical and clinical studies, resulting in significant changes in toxicology, pharmacokinetics and efficacy. These effects result from the generation of drug-induced (neutralizing) autoantibodies against Denosumab and can be responsible for allergic reaction, or even anaphylactic shock. This ELISA kit detects antibodies for Anti-Denosumab and may be used for monitoring immunogenicity.

Related Products

Denosumab ELISA Assay Kit
Anti-Atezolizumab (Tecentriq) ELISA Assay Kit
Anti-Daratumumab (Darzalex) ELISA Assay Kit

Additional Information

Assay Principle

The method employs the quantitative sandwich enzyme immunoassay technique. Denosumab is pre-coated onto microwells. Samples and standards are pipetted into microwells and antibodies to Denosumab present in the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated Denosumab is pipetted and incubated. After washing microwells in order to remove any nonspecific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Anti-Denosumab in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.

Package Inserts

Please note: All documents above are for reference use only and should not be used in place of the documents included with this physical product. If digital copies are needed, please contact us.

Product Citations